Thursday – Clinical Track 3A

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2026.

Please evaluate the speakers

Topic and Speaker(s)
ExcellentGoodFairPoor
Dosage conversion among different BTX preparations: Is there pharmacological evidence?
Joaquim Ferreira, MD, PhD (Portugal)
Clinical relevance of neutralizing antibodies
Philipp Albrecht, MD (Germany)
Adherence and dropout in BoNT therapy
David Simpson, MD (USA)
Physician Assessment of Non-Medical Toxin Switching on Patient Care
David Charles, MD (USA)
YesNo
Dosage conversion among different BTX preparations: Is there pharmacological evidence?
Joaquim Ferreira, MD, PhD (Portugal)
Clinical relevance of neutralizing antibodies
Philipp Albrecht, MD (Germany)
Adherence and dropout in BoNT therapy
David Simpson, MD (USA)
Physician Assessment of Non-Medical Toxin Switching on Patient Care
David Charles, MD (USA)
YesNo
Dosage conversion among different BTX preparations: Is there pharmacological evidence?
Joaquim Ferreira, MD, PhD (Portugal)
Clinical relevance of neutralizing antibodies
Philipp Albrecht, MD (Germany)
Adherence and dropout in BoNT therapy
David Simpson, MD (USA)
Physician Assessment of Non-Medical Toxin Switching on Patient Care
David Charles, MD (USA)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Scam Warning

Due to scam emails being sent, please note that INA will NOT email you to wire money to anyone on the Board of Directors or anyone else from the INA.

Join Our Mailing List

Click here to sign up, and then manage your subscription.